Form 8-K - Current report:
SEC Accession No. 0001140361-24-036934
Filing Date
2024-08-13
Accepted
2024-08-13 07:23:44
Documents
15
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20034043_8k.htm   iXBRL 8-K 32506
2 EXHIBIT 99.1 ef20034043_ex99-1.htm EX-99.1 174199
6 image00004.jpg GRAPHIC 2577
  Complete submission text file 0001140361-24-036934.txt   363065

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20240813.xsd EX-101.SCH 3856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20240813_lab.xml EX-101.LAB 22690
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20240813_pre.xml EX-101.PRE 16546
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20034043_8k_htm.xml XML 4213
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 241198775
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)